Show MeYes, B12 injections are effective for peripheral neuropathy, but only under a specific condition: the neuropathy must be caused by vitamin B12 deficiency. In that case, injections reliably halt progression and often reverse symptoms, with improvement typically beginning at 6 to 12 weeks and continuing for 6 to 12 months. In neuropathy from diabetes, chemotherapy, alcohol, or unknown causes, injections do not repair damaged nerves and are not a proven treatment. Roughly 10 to 30 percent of peripheral neuropathy cases have a detectable nutritional or metabolic cause, and B12 deficiency is among the most treatable.
How B12 Deficiency Damages Nerves: The Mechanism
Vitamin B12 (cobalamin) is a cofactor for two enzymes that matter to nerve tissue. The first is methionine synthase, which regenerates methionine from homocysteine and maintains the methylation reactions that build myelin. The second is methylmalonyl-CoA mutase, which converts methylmalonyl-CoA to succinyl-CoA. When B12 is low, methylmalonic acid (MMA) accumulates and is incorporated into fatty acids of the myelin sheath.
This produces a specific pattern: subacute combined degeneration of the spinal cord, affecting the dorsal columns (vibration and position sense) and the corticospinal tracts (motor function). Peripheral nerves demyelinate as well. The result is symmetric numbness and tingling in the feet and hands, loss of balance in the dark, and sometimes weakness.
In plain terms: B12 is a raw material for the insulation around nerves, and without it the insulation degrades from the spinal cord outward.
The critical detail is that demyelination is reversible early and becomes axonal loss later. Once axons degenerate, recovery is partial at best. This is why time to treatment—not dose—is the strongest predictor of outcome.
What the Numbers Say: Deficiency Prevalence and Diagnostic Thresholds
Serum B12 below 200 pg/mL is conventionally deficient, and 200 to 300 pg/mL is borderline. But serum B12 is an unreliable test: it measures total B12, not the functional fraction, and roughly 30 to 50 percent of patients with true tissue deficiency have serum levels in the low-normal range.
The functional markers are more sensitive. Methylmalonic acid above 0.4 micromol/L and homocysteine above 15 micromol/L suggest tissue deficiency even when serum B12 looks acceptable. In older adults, the Framingham Offspring study found that nearly 40 percent of people with serum B12 under 350 pg/mL had elevated MMA, indicating functional deficiency missed by the standard cutoff.
Risk groups matter for the pretest probability. Per the FDA-approved prescribing information for cyanocobalamin injection, deficiency is most common in pernicious anemia (affecting roughly 1 in 1,000 people in the general population but up to 1 to 2 percent of people over 60), strict vegans, people who have had gastric or ileal surgery, long-term metformin users (about 6 to 30 percent develop low B12 depending on duration), and long-term proton pump inhibitor users.
| Marker | Normal | Borderline | Deficient |
|---|---|---|---|
| Serum B12 | above 300 pg/mL | 200–300 pg/mL | below 200 pg/mL |
| Methylmalonic acid | below 0.27 micromol/L | 0.27–0.4 micromol/L | above 0.4 micromol/L |
| Homocysteine | below 10 micromol/L | 10–15 micromol/L | above 15 micromol/L |
Reconciling the two thresholds: serum B12 under 200 pg/mL is definitive, but a value between 200 and 300 pg/mL is treated as deficient if MMA or homocysteine is elevated—so the functional test overrides a borderline serum value.
Injection Versus Oral: A Quantified Comparison
Injections bypass absorption entirely, which matters because B12 absorption requires gastric intrinsic factor and an intact terminal ileum. Any defect in that chain—pernicious anemia, atrophic gastritis, bariatric surgery, ileal resection—makes oral absorption unreliable. High-dose oral B12 (1,000 to 2,000 micrograms daily) can overcome absorption defects by passive diffusion, delivering roughly 1 percent of the dose without intrinsic factor, but it depends on adherence and is less predictable in severe malabsorption.
| Feature | Intramuscular injection | High-dose oral tablet |
|---|---|---|
| Standard regimen | 1,000 mcg IM daily or every other day × 1–2 weeks, then monthly | 1,000–2,000 mcg daily |
| Absorption route | Complete, bypasses gut | Passive diffusion, about 1% of dose |
| Onset of serum correction | 24–72 hours | 1–4 weeks |
| Cost (US, approximate) | USD 30–80 per injection visit | USD 10–40 per month |
| Best for | Severe deficiency, malabsorption, neurologic symptoms | Maintenance, mild deficiency, adherence-friendly patients |
| Key limitation | Clinic visits, injection burden | Unreliable in pernicious anemia and post-surgical gut |
For neuropathy specifically, guidelines favor injections initially. The 2020 British Society for Haematology guidance treats neurological involvement as an indication for parenteral therapy first, because the consequences of undertreated nerve damage are irreversible.
Timeline of Recovery: What to Expect and When
Recovery follows a predictable but slow arc. Serum B12 normalizes within days; nerve symptoms lag by weeks to months because remyelination is a biological rebuild, not a chemical correction. The timeline below reflects typical courses in confirmed deficiency-related neuropathy.
| Timepoint | What changes | Expected degree of improvement |
|---|---|---|
| 0–72 hours | Serum B12 normalizes; MMA and homocysteine begin falling | No symptom change |
| 1–2 weeks | Loading injections completed; hematologic response (if anemia) | Fatigue and anemia improve; neuropathy unchanged |
| 4–6 weeks | Early remyelination begins | Tingling may soften; numbness usually unchanged |
| 3 months | Substantial remyelination in mild cases | 30–50% report reduced paresthesia |
| 6 months | Plateau approaching for sensory symptoms | Most recovery achieved in mild-to-moderate cases |
| 12 months | Maximum likely recovery | Residual numbness common if axonal loss occurred |
| Beyond 12 months | Little further gain | Persistent deficits reflect irreversible axonal damage |
The single most useful expectation-setting number: patients with symptoms present under 6 months recover far more completely than those with symptoms over 12 months. Duration of symptoms before treatment is the dominant prognostic variable.
When Injections Do Not Help: Misconceptions and Edge Cases
The most common misconception is that B12 injections treat neuropathy of any cause. They do not. In diabetic peripheral neuropathy, B12 supplementation helps only the subset with concurrent deficiency (metformin use raises this risk substantially). In chemotherapy-induced neuropathy, alcohol-related neuropathy, and idiopathic small-fiber neuropathy, correcting B12 treats a comorbidity, not the neuropathy itself.
A second misconception is that more frequent injections accelerate nerve recovery. Once tissue stores are replete, additional B12 is excreted in urine; there is no dose-response for nerve repair above sufficiency. Very high doses do not speed remyelination.
A non-obvious caveat: B12 can mask folate deficiency while allowing neurologic damage to progress, and treating B12 deficiency without checking folate can unmask or worsen anemia. Folate and B12 should be assessed together. A second caveat concerns nitrous oxide exposure—even brief anesthesia can precipitate acute neurologic deterioration in people with unrecognized B12 deficiency, so deficiency should be corrected before elective procedures involving nitrous oxide.
Practical Steps: Testing, Treating, and Monitoring
The action sequence is diagnostic first, therapeutic second. Treating empirically without confirming the cause risks missing a treatable diagnosis or attributing irreversible neuropathy to a vitamin.
- Test serum B12 plus methylmalonic acid and homocysteine before starting therapy; a borderline serum level with elevated functional markers confirms deficiency.
- Investigate the cause: intrinsic factor antibodies for pernicious anemia, review of metformin and PPI use, dietary history, and prior gastric or ileal surgery.
- Start parenteral B12 for neurologic symptoms rather than oral therapy, per hematology guidance, then transition to oral or monthly injection for maintenance once repletion is confirmed.
- Recheck MMA and homocysteine at 8 to 12 weeks to confirm biochemical correction, not just a normal serum B12.
- Track symptoms objectively—vibration sense, monofilament testing, gait—at 3, 6, and 12 months rather than relying on subjective tingling alone.
- Do not stop maintenance therapy in pernicious anemia; lifelong replacement is required, and relapse of neuropathy can occur within months of cessation.
Limits of the Evidence and What Remains Uncertain
The evidence base for B12 in deficiency neuropathy is strong for biochemical correction and moderate for symptomatic reversal. Most data come from observational cohorts and small trials, not large randomized controlled trials, because randomizing known-deficient patients to placebo is considered unethical. The precise proportion who recover fully remains uncertain and varies with symptom duration, age, and the degree of axonal loss at diagnosis.
Whether B12 helps neuropathy in people without documented deficiency is not established. Trials of B12 supplementation in diabetic neuropathy without deficiency have shown inconsistent, mostly negative results, and no major guideline endorses it for that use. Claims that injections reverse neuropathy in people with normal B12 status outrun the evidence.
The honest bottom line: B12 injections are highly effective, time-sensitive treatment for deficiency-related neuropathy and ineffective as a general neuropathy remedy. The deciding factors are the cause, the functional lab markers, and how long the nerves have been damaged before treatment begins.